Zimmer Biomet Holdings, Inc. (ZBH) P/E Ratio History
UndervaluedTrading at 24.8x vs 5Y avg 48.2x · 30th percentile · Below historical baseline · Data 2001–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Zimmer Biomet Holdings, Inc. (ZBH) trades at a price-to-earnings ratio of 24.8x, with a stock price of $87.97 and trailing twelve-month earnings per share of $3.89.
The current P/E is 49% below its 5-year average of 48.2x. Over the past five years, ZBH's P/E has ranged from a low of 20.5x to a high of 124.5x, placing the current valuation at the 30th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ZBH is roughly in line with its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, ZBH trades roughly in line with the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ZBH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ZBH Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ZBH P/E vs Peers
Orthopedics, spine, and sports medicine peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $118B | 36.6 | 2.46 | +8% | |
| $67B | 23.3 | - | +55% | |
| $102B | 22.0 | - | +31% | |
| $13B | 20.9 | 2.93 | +53% | |
| $11B | 20.2 | 0.65Best | +423%Best | |
| $550B | 39.4 | - | -58% | |
| $62M | 14.7Lowest | - | +125% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ZBH Historical P/E Data (2001–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $90.42 | $3.85 | 23.5x | -47% |
| FY2025 Q4 | Dec 31 2025 | $89.92 | $3.54 | 25.4x | -42% |
| FY2025 Q3 | - | $98.50 | $4.04 | 24.4x | -45% |
| FY2025 Q2 | Jun 30 2025 | $91.21 | $4.11 | 22.2x | -50% |
| FY2025 Q1 | Mar 31 2025 | $113.18 | $4.52 | 25.0x | -43% |
| FY2024 Q4 | - | $105.63 | $4.45 | 23.7x | -46% |
| FY2024 Q3 | Sep 30 2024 | $107.95 | $5.26 | 20.5x | -53% |
| FY2024 Q2 | Jun 30 2024 | $108.53 | $4.80 | 22.6x | -49% |
| FY2024 Q1 | Mar 31 2024 | $131.98 | $4.62 | 28.6x | -35% |
| FY2023 Q4 | Dec 31 2023 | $121.70 | $4.89 | 24.9x | -43% |
| FY2023 Q3 | Sep 30 2023 | $112.22 | $2.26 | 49.7x | +13% |
| FY2023 Q2 | Jun 30 2023 | $145.60 | $2.41 | 60.4x | +37% |
| FY2023 Q1 | Mar 31 2023 | $129.20 | $2.14 | 60.4x | +37% |
| FY2022 Q4 | Dec 31 2022 | $127.50 | $1.10 | 116.2x | +164% |
| FY2022 Q3 | Sep 30 2022 | $104.55 | $1.32 | 79.3x | +80% |
| FY2022 Q2 | - | $105.06 | $1.09 | 96.6x | +119% |
| FY2022 Q1 | - | $127.90 | $1.03 | 124.5x | +183% |
| FY2021 Q4 | Dec 31 2021 | $123.24 | $1.90 | 64.9x | +47% |
| FY2021 Q3 | - | $141.99 | $3.89 | 36.5x | -17% |
| FY2021 Q2 | Jun 30 2021 | $156.02 | $4.36 | 35.8x | -19% |
| FY2021 Q1 | Mar 31 2021 | $155.30 | $2.69 | 57.7x | +31% |
| FY2020 Q2 | - | $115.79 | $0.16 | 723.7x | +1543% |
| FY2020 Q1 | - | $98.06 | $1.81 | 54.2x | +23% |
| FY2019 Q4 | - | $145.21 | $5.47 | 26.5x | -40% |
| FY2018 Q3 | Sep 30 2018 | $127.54 | $8.70 | 14.7x | -67% |
| FY2018 Q2 | Jun 30 2018 | $108.11 | $8.39 | 12.9x | -71% |
| FY2018 Q1 | Mar 31 2018 | $105.78 | $8.39 | 12.6x | -71% |
| FY2017 Q4 | Dec 31 2017 | $117.06 | $9.01 | 13.0x | -71% |
| FY2017 Q3 | Sep 30 2017 | $113.59 | $3.18 | 35.7x | -19% |
| FY2017 Q2 | Jun 30 2017 | $124.56 | $3.48 | 35.8x | -19% |
| FY2017 Q1 | Mar 31 2017 | $118.46 | $2.42 | 49.0x | +11% |
| FY2016 Q4 | Dec 31 2016 | $100.12 | $1.47 | 68.1x | +55% |
| FY2016 Q3 | Sep 30 2016 | $126.14 | $1.77 | 71.3x | +62% |
| FY2016 Q2 | - | $116.78 | $1.10 | 106.2x | +141% |
| FY2016 Q1 | - | $103.44 | $0.35 | 295.5x | +571% |
| FY2015 Q4 | - | $99.52 | $0.85 | 117.1x | +166% |
| FY2015 Q3 | Sep 30 2015 | $91.12 | $1.13 | 80.6x | +83% |
| FY2015 Q2 | - | $105.97 | $1.98 | 53.5x | +22% |
| FY2015 Q1 | - | $114.01 | $3.92 | 29.1x | -34% |
| FY2014 Q4 | Dec 31 2014 | $110.03 | $4.19 | 26.3x | -40% |
| FY2014 Q3 | - | $97.55 | $4.64 | 21.0x | -52% |
| FY2014 Q2 | Jun 30 2014 | $100.76 | $4.58 | 22.0x | -50% |
| FY2014 Q1 | Mar 31 2014 | $91.75 | $4.44 | 20.7x | -53% |
| FY2013 Q4 | - | $90.41 | $4.43 | 20.4x | -54% |
| FY2013 Q3 | Sep 30 2013 | $79.69 | $3.97 | 20.1x | -54% |
| FY2013 Q2 | Jun 30 2013 | $72.70 | $4.09 | 17.8x | -60% |
| FY2013 Q1 | Mar 31 2013 | $72.97 | $4.42 | 16.5x | -63% |
| FY2012 Q4 | Dec 31 2012 | $64.67 | $4.31 | 15.0x | -66% |
| FY2012 Q3 | Sep 30 2012 | $65.60 | $4.29 | 15.3x | -65% |
| FY2012 Q2 | Jun 30 2012 | $62.44 | $4.28 | 14.6x | -67% |
| FY2012 Q1 | Mar 31 2012 | $62.36 | $4.12 | 15.1x | -66% |
| FY2011 Q4 | Dec 31 2011 | $51.82 | $4.03 | 12.9x | -71% |
| FY2011 Q3 | Sep 30 2011 | $51.88 | $3.33 | 15.6x | -65% |
| FY2011 Q2 | - | $61.31 | $3.28 | 18.7x | -58% |
| FY2011 Q1 | - | $58.72 | $3.04 | 19.3x | -56% |
| FY2010 Q4 | Dec 31 2010 | $52.08 | $2.97 | 17.5x | -60% |
| FY2010 Q3 | - | $50.77 | $3.55 | 14.3x | -68% |
| FY2010 Q2 | Jun 30 2010 | $52.44 | $3.29 | 15.9x | -64% |
| FY2010 Q1 | Mar 31 2010 | $57.43 | $3.44 | 16.7x | -62% |
| FY2009 Q4 | - | $57.34 | $3.34 | 17.2x | -61% |
| FY2009 Q3 | Sep 30 2009 | $51.85 | $3.33 | 15.6x | -65% |
| FY2009 Q2 | - | $41.33 | $3.58 | 11.5x | -74% |
| FY2009 Q1 | - | $35.41 | $3.60 | 9.8x | -78% |
| FY2008 Q4 | Dec 31 2008 | $39.21 | $3.71 | 10.6x | -76% |
| FY2008 Q3 | - | $62.63 | $4.09 | 15.3x | -65% |
| FY2008 Q2 | Jun 30 2008 | $66.02 | $3.33 | 19.8x | -55% |
| FY2008 Q1 | Mar 31 2008 | $75.53 | $3.31 | 22.8x | -48% |
| FY2007 Q4 | Dec 31 2007 | $64.17 | $3.27 | 19.6x | -55% |
| FY2007 Q3 | Sep 30 2007 | $78.57 | $3.16 | 24.9x | -44% |
| FY2007 Q2 | Jun 30 2007 | $82.35 | $3.73 | 22.1x | -50% |
| FY2007 Q1 | Mar 31 2007 | $82.86 | $3.57 | 23.2x | -47% |
| FY2006 Q4 | Dec 31 2006 | $76.04 | $3.41 | 22.3x | -49% |
| FY2006 Q3 | Sep 30 2006 | $65.48 | $3.19 | 20.5x | -53% |
| FY2006 Q2 | Jun 30 2006 | $55.03 | $3.10 | 17.8x | -60% |
| FY2006 Q1 | Mar 31 2006 | $65.58 | $3.05 | 21.5x | -51% |
| FY2005 Q4 | Dec 31 2005 | $65.43 | $2.93 | 22.3x | -49% |
| FY2005 Q3 | Sep 30 2005 | $66.83 | $2.93 | 22.8x | -48% |
| FY2005 Q2 | - | $73.89 | $2.78 | 26.6x | -40% |
| FY2005 Q1 | - | $75.49 | $2.49 | 30.3x | -31% |
| FY2004 Q4 | Dec 31 2004 | $77.73 | $2.19 | 35.5x | -19% |
| FY2004 Q3 | - | $76.68 | $1.54 | 49.8x | +13% |
| FY2004 Q2 | Jun 30 2004 | $85.56 | $1.45 | 59.0x | +34% |
| FY2004 Q1 | Mar 31 2004 | $71.58 | $1.43 | 50.1x | +14% |
| FY2003 Q4 | Dec 31 2003 | $68.30 | $1.71 | 39.9x | -9% |
| FY2003 Q3 | - | $53.45 | $1.92 | 27.8x | -37% |
| FY2003 Q2 | Jun 30 2003 | $43.70 | $1.82 | 24.0x | -45% |
| FY2003 Q1 | Mar 31 2003 | $47.18 | $1.71 | 27.6x | -37% |
| FY2002 Q4 | - | $40.28 | $1.31 | 30.7x | -30% |
| FY2002 Q3 | Sep 30 2002 | $37.19 | $1.17 | 31.8x | -28% |
| FY2002 Q2 | Jun 30 2002 | $34.59 | $0.98 | 35.3x | -20% |
| FY2002 Q1 | Mar 31 2002 | $33.03 | $0.86 | 38.4x | -13% |
| FY2001 Q4 | Dec 31 2001 | $29.63 | $0.77 | 38.5x | -13% |
| FY2001 Q3 | Sep 30 2001 | $26.92 | $0.80 | 33.6x | -24% |
Average P/E for displayed period: 44.0x
Full Stock Analysis
Deep dive into ZBH consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ZBH — Frequently Asked Questions
Quick answers to the most common questions about buying ZBH stock.
What is ZBH's P/E ratio?
Zimmer Biomet Holdings, Inc. (ZBH) trailing twelve-month P/E ratio is 24.8x, based on TTM diluted EPS of $3.89. The 5-year average P/E is 48.2x and the historical range spans 20.5x to 124.5x.
Is ZBH stock overvalued or undervalued?
ZBH trades at 24.8x P/E, below its 5-year average of 48.2x. At the 30th percentile of its historical range (20.5x–124.5x), the stock is priced at a discount to its own history.
Is ZBH stock expensive?
No, ZBH is not expensive on a historical basis. The current P/E of 24.8x is below the 5-year average of 48.2x and sits at the 30th percentile of its valuation range.
What is ZBH's historical P/E range?
Over the past 5 years, ZBH's P/E ratio has ranged from 20.5x to 124.5x, with a median of 35.8x and an average of 48.2x. The current P/E of 24.8x places the stock at the 30th percentile of this range. Full historical data spans 2001–2026.
How does ZBH's P/E compare to the S&P 500?
ZBH trades at 24.8x P/E versus the S&P 500 median of 24.4x. The 2% premium to the market typically reflects higher expected earnings growth or quality.
How does ZBH's valuation compare to Healthcare peers?
Zimmer Biomet Holdings, Inc. P/E of 24.8x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ZBH's PEG ratio?
ZBH PEG ratio is N/A, based on a P/E of 24.8x and EPS growth of -19.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ZBH's earnings yield?
ZBH earnings yield is 4.04%, the inverse of its 24.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.